ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

SPPI Spectrum Pharmaceuticals Inc

1.03
0.00 (0.00%)
Pre Market
Last Updated: 01:00:00
Delayed by 15 minutes
Share Name Share Symbol Market Type
Spectrum Pharmaceuticals Inc NASDAQ:SPPI NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 1.03 1.14 0.9785 0 01:00:00

INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Spectrum Pharmaceuticals, Inc. of Pendency of Class Action Laws...

09/12/2015 8:23pm

PR Newswire (US)


Spectrum Pharmaceuticals (NASDAQ:SPPI)
Historical Stock Chart


From May 2019 to May 2024

Click Here for more Spectrum Pharmaceuticals Charts.

NEW YORK, Dec. 9, 2015 /PRNewswire/ -- The following statement is being issued by Levi & Korsinsky, LLP:

Levi & Korsinsky, LLP

To: All persons or entities who purchased or otherwise acquired securities of Spectrum Pharmaceuticals, Inc. ("Spectrum Pharmaceuticals") (NASDAQGS: SPPI) between May 7, 2015 and October 23, 2015.      

You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the District of Nevada. If you purchased or otherwise acquired Spectrum Pharmaceuticals between May 7, 2015 and October 23, 2015, your rights may be affected by this action. To get more information go to: http://zlk.9nl.com/spectrump or contact Joseph E. Levi, Esq. either via email at jlevi@zlk.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.

The complaint alleges that Spectrum Pharmaceuticals violated federal securities laws by disseminating materially false and misleading information and failing to disclose material facts, causing the stock to trade at artificially inflated prices.

On October 23, 2015, Spectrum announced that it has received a Complete Response Letter from the U.S. Food and Drug Administration (FDA) in response to its New Drug Application seeking clearance for Evomela, indicating that the FDA cannot approve the application in its present form. Upon this news, shares of Spectrum Pharmaceuticals fell more than 20% on intraday trading.

If you suffered a loss in Spectrum Pharmaceuticals you have until January 4, 2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Levi & Korsinsky is a national firm with offices in New York, New Jersey, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation involving financial fraud, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:    
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
30 Broad Street - 24th Floor
New York, NY 10004
Tel: (212) 363-7500
Toll Free:  (877) 363-5972
Fax: (212) 363-7171
www.zlk.com

Logo - http://photos.prnewswire.com/prnh/20120409/MM84375LOGO

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/investor-alert-levi--korsinsky-llp-reminds-shareholders-of-spectrum-pharmaceuticals-inc-of-pendency-of-class-action-lawsuit-and-a-lead-plaintiff-deadline-of-january-4-2016--sppi-300190744.html

SOURCE Levi & Korsinsky, LLP

Copyright 2015 PR Newswire

1 Year Spectrum Pharmaceuticals Chart

1 Year Spectrum Pharmaceuticals Chart

1 Month Spectrum Pharmaceuticals Chart

1 Month Spectrum Pharmaceuticals Chart

Your Recent History

Delayed Upgrade Clock